ClinicalTrials.gg
CompletedNCT01728064Updated Aug 31, 2020

Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia

A Phase 2 interventional study of Placebo and EPI-743 400 mg in Friedreich's Ataxia, sponsored by PTC Therapeutics. Completed at 3 sites in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2020-08-31.

Sponsored by PTC Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.

Planned enrollment
15th of 49
60 · median 32
Started
2012
with 1 other
Phase 2
14 of 71
3 open now
Registered
10th of 71
by date
Lead sponsor
6 of 71
PTC Therapeutics

Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 15th largest by planned enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2012, is one of 14 in phase 2, and was the 10th registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Friedreich Ataxia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to examine the effects of EPI-743 on visual function and neurologic function in patients with Friedreich's ataxia.

03

Conditions studied

  • Friedreich's Ataxia

Keywords

  • Friedreich's
  • Ataxia
  • FRDA
  • FA
  • EPI-743
  • Edison
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of genetically confirmed Friedreich's ataxia
  2. Visual acuity at baseline more than 15 letters on EDTRS at four meters
  3. FARS score of 20 to 90
  4. Agreement to use if within reproductive years (see specifics in section D1, page 21)
  5. Hormone replacement therapy, if used, must remain stable for the duration of the study
  6. Willingness and ability to comply with study procedures
  7. Willingness and ability to arrive at study site day prior to evaluations
  8. Abstention from use of dietary supplements and non-prescribed medications at least 30 days prior to initiation of treatment and for the duration of the study. This would specifically include idebenone, Coenzyme Q10 and vitamin E
  9. Abstention from use of other investigative or non-approved drugs within 30 days of enrollment and for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Allergy to EPI-743 or sesame oil or nuts
  2. bleeding condition or abnormal PT/ INR (INR > two; PTT > two-times normal)
  3. Liver insufficiency with LFTs greater than three-times upper normal limit at screening
  4. Renal insufficiency with creatinine > 1.5 at screening
  5. Fat malabsorption syndromes
  6. Any other respiratory chain diseases of the mitochondria or inborn errors of metabolism
  7. Any other ophthalmologic conditions
  8. History of alcohol or drug abuse
  9. Clinically significant cardiomyopathy with \< 40 percent at screening
  10. Clinically significant arrhythmia within past two years requiring treatment
  11. Anticoagulant therapy within 30 days of enrollment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo capsules three times daily

    Drug: Placebo

  • Active comparator
    EPI-743 400 mg

    EPI-743 at a dose of 400 mg three times daily

    Drug: EPI-743 400 mg

  • Active comparator
    EPI-743 200 mg

    EPI-743 at a dose of 200 mg three times daily

    Drug: EPI-743 200 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Visual Function

    Low contrast visual acuity

Secondary outcomes

  1. Color vision

    Roth 28 hue test

  2. Neurologic function

    Friedreich's ataxia rating scale

  3. Neuromuscular function

    25-foot walk test

  4. Neuromuscular function

    9-hole peg test

  5. Quality of life

    SF-36

  6. Disease biomarkers

    Blood biomarker levels

  7. Cardiac function

    Echocardiogram

  8. Safety

    Number of adverse events

  9. Disease improvement

    Patient Global Improvement Scale

  10. Visual Function

    Visual field exam

    Time frame: Baseline, Months 3, 6, 9 and 12

07

Study locations

3 sites
  • University of California Los Angeles
    Los Angeles, California 90095, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Childrens Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2012 to primary completion in Oct 2015, 34 months.

Of 12 phase 2 interventional studies under Friedreich Ataxia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 34. This study's 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2012
First posted
Nov 16, 2012
StartActual
Dec 31, 2012
Primary completionActual
Oct 31, 2015
CompletionActual
Feb 29, 2016
Results delay requested
Aug 17, 2020
Last update
Aug 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01728064
Lead sponsor
PTC Therapeutics
Responsible party
Sponsor
First posted
Nov 16, 2012
Start date
Dec 31, 2012
Primary completion
Oct 31, 2015
Completion
Feb 29, 2016
Last update
Aug 31, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha-tocotrienol quinone

Start the discussion